Stock Traders Buy Large Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics Inc (NASDAQ:CAPR) was the target of some unusual options trading on Thursday. Stock investors acquired 9,551 call options on the company. This is an increase of 174% compared to the typical volume of 3,481 call options.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of CAPR. Summit Investment Advisors Inc. increased its holdings in Capricor Therapeutics by 54.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 1,345 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 2,947 shares during the last quarter. Virtus ETF Advisers LLC acquired a new position in Capricor Therapeutics in the fourth quarter valued at approximately $68,000. AlphaQuest LLC acquired a new position in shares of Capricor Therapeutics in the 4th quarter valued at $78,000. Finally, New York State Common Retirement Fund boosted its stake in Capricor Therapeutics by 625.0% in the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 5,000 shares in the last quarter. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Trading Up 15.0 %

NASDAQ CAPR traded up $1.45 on Thursday, reaching $11.09. 897,852 shares of the company were exchanged, compared to its average volume of 1,463,060. Capricor Therapeutics has a fifty-two week low of $3.52 and a fifty-two week high of $23.40. The stock has a market capitalization of $506.56 million, a P/E ratio of -10.50 and a beta of 4.65. The business’s fifty day moving average price is $12.43 and its 200 day moving average price is $15.10.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.15. The firm had revenue of $11.13 million during the quarter, compared to analysts’ expectations of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. Equities research analysts forecast that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Analyst Ratings Changes

CAPR has been the topic of a number of research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $30.00 target price on shares of Capricor Therapeutics in a research report on Thursday, March 20th. HC Wainwright restated a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research note on Monday, March 17th. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Based on data from MarketBeat, Capricor Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.